Generic Name and Formulations:
Armodafinil 50mg, 150mg, 200mg, 250mg; tabs.
Indications for NUVIGIL:
To improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), narcolepsy and shift work sleep disorder (SWSD). Adjunct to standard treatment for underlying airway obstruction in OSAHS.
≥17yrs: OSAHS, narcolepsy: 150mg or 250mg once daily in the AM. SWSD: 150mg one hour before starting shift. Severe hepatic impairment: reduce dose.
<17yrs: not recommended.
Discontinue if rash, sores, blistering, or ulceration appears (unless clearly not drug-related), or if angioedema, anaphylaxis, or DRESS/multi-organ hypersensitivity reaction occurs. OSAHS: treat underlying obstruction; maintain CPAP use if indicated. History of LV hypertrophy or mitral valve prolapse syndrome (eg, ischemic ECG changes, chest pain, arrhythmias associated with CNS stimulants): not recommended. Recent MI. Unstable angina. Monitor BP. History of psychosis, depression, or mania; consider discontinuing if psychiatric symptoms develop. Severe hepatic or renal impairment. Reevaluate periodically. Elderly (may need to reduce dose). Labor & delivery. Pregnancy. Nursing mothers.
May antagonize hormonal contraceptives; use alternative or additional contraception during and for 1 month after. Avoid alcohol. Caution with MAOIs. Armodafinil levels may be decreased by CYP3A4 inducers (eg, carbamazepine, phenobarbital, rifampin) and increased by CYP3A4 inhibitors (eg, ketoconazole, erythromycin). May reduce levels of drugs metabolized by CYP3A4 (eg, cyclosporine). May increase levels of drugs metabolized by CYP2C9 (eg, warfarin) or CYP2C19 (eg, phenytoin, diazepam, propranolol).
Headache, insomnia, other CNS effects, GI upset; rash (may be serious, eg, Stevens-Johnson, toxic epidermal necrolysis), DRESS/multiorgan hypersensitivity.
Register pregnant patients exposed to Nuvigil by calling (866) 404-4106.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking